Project Grant R03TR004848
Award Date
6/15/25
Completion Date
6/14/26
Dollars Obligated
$178K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, will fund research to develop a treatment for Familial Platelet Disorder with Myeloid Malignancy (FPDMM), a rare genetic disorder affecting hundreds of people in the U.S. The $489,500 award to The Children's Hospital of Philadelphia will support studies on the small compound Repsox, which has shown promise in correcting the platelet defects and reducing leukemia risk in FPDMM. The...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will provide $696,870 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) from August 1, 2024 to May 31, 2028. The primary focus of this award is to conduct research on the functional characterization of the endothelial cell niche for hematopoietic stem...
The federal Project Grant award in the amount of $617,367 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is being used by the Children's Hospital Corporation, doing business as Boston Children's Hospital, to conduct research on "BASE EDITING TO IMPROVE CONDITIONING AND TRANSPLANT OF BONE MARROW FAILURE PATIENTS". The research project aims to leverage innovative gene editing techniques to enhance the...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,500 project grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to investigate clonal evolution in Fanconi anemia. The grant period runs from September 30, 2023 to September 29, 2026. As a non-profit pediatric teaching hospital and research center, Boston Children's Hospital will leverage its expertise in pediatric medicine, genomics, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $734,607 to Boston Medical Center Corporation to conduct research on the mechanisms regulating the migration of hematopoietic stem cells (HSCs) into the bone marrow niche. The goal is to elucidate the key endothelial cell processes, including adhesion and endocytosis/vesicle trafficking, that facilitate the trans-endothelial...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,416,000 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital), a non-profit teaching hospital and research center affiliated with Harvard Medical School. The grant, titled "IND-ENABLING STUDIES OF POLYMERASE INHIBITORS FOR BMF DUE TO TELOMERE EXHAUSTION", will support a 2-year research project from Sep 1, 2023 to Aug 31, 2025. Through this funding, Boston...
This $159,512 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the generation of a comprehensive single-cell transcriptomic and epigenomic map of human bone marrow cells. The project aims to establish the mesenchymal cell hierarchy in human bone, providing insight into how cell fates are regulated and the cell-cell interactions that support cell fate decisions. This will involve isolating single-cell suspensions from...
This Project Grant award, titled "MULTIPLEX EPITOPE EDITING TO ENABLE NOVEL IMMUNOTHERAPIES FOR ACUTE MYELOID LEUKEMIA", is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The $2,282,666 award to The Children's Hospital Corporation, doing business as Boston Children's Hospital, aims to develop innovative immunotherapy approaches for acute myeloid leukemia (AML) by genetically engineering hematopoietic stem/progenitor cells to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $120,375 to Childrens Hospital Medical Center in Cincinnati, Ohio to develop advanced mouse models for studying the pathogenesis of myelodysplastic syndromes (MDS) caused by DDX41 gene mutations. The project aims to create genetic mouse models that accurately reflect the natural progression of DDX41-mutated MDS,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $497,806.97 to the Trustees of Indiana University, doing business as Indiana University Indianapolis, for a 3-year research project. The research aims to elucidate molecular programs that can be targeted to enhance the function of hematopoietic stem cells (HSCs) derived from umbilical cord blood, with the goal of improving hematopoietic...